Tygacil (tigecycline) injection — CareFirst (Caremark)
Complicated skin and skin structure infections caused by susceptible isolates of Escherichia coli, Enterococcus faecalis (vancomycin-susceptible isolates), Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Streptococcus agalactiae, Streptococcus anginosus group (includes S. anginosus, S. intermedius, and S. constellatus), Streptococcus pyogenes, Enterobacter cloacae, Klebsiella pneumoniae, and Bacteroides fragilis in adults age ≥ 18 years
Initial criteria
- Tygacil is not indicated for the treatment of diabetic foot infections
- Tygacil is not indicated for the treatment of hospital-acquired or ventilator-associated pneumonia
- To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tygacil and other antibacterial drugs, Tygacil should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria
- Appropriate specimens for bacteriological examination should be obtained to isolate and identify the causative organisms and determine their susceptibility to tigecycline